

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-31 (canceled).

32. (currently amended) A peptide compound ~~capable of specific interaction with parkin,~~  
~~wherein the compound is a peptide~~ having an amino acid sequence of at least 95% identity  
to the full length human PAP1 sequence of SEQ ID NO: 2.

33. (previously presented) A peptide compound as claimed in claim 32, which inhibits the  
interaction between PAP1 and parkin.

Claims 34-38 (canceled).

39. (previously presented) An isolated peptide or polypeptide comprising the amino acid  
sequence of SEQ ID NO. 2.

Claims 40-52 (canceled).

53. (previously presented) A composition comprising a peptide compound as claimed in  
claim 32 and a pharmaceutically acceptable vehicle or excipient.

Claims 54-58 (canceled).

59. (previously presented) A composition comprising a peptide compound as claimed in  
claim 32, and a carrier.

Claims 60-65 (canceled).